Cholesterol drug mipomersen meets goal of Phase III study

02/10/2010 | Boston Globe (tiered subscription model), The · Forbes

Genzyme and Isis Pharmaceuticals reported that their drug mipomersen lowered the level of LDL "bad" cholesterol by 28% in patients with heterozygous familial hypercholesterolemia, compared with a 5% reduction in those taking placebo. Positive results of the late-stage trial put the company "on track with our development plan for mipomersen," a Genzyme official said.

View Full Article in:

Boston Globe (tiered subscription model), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX